Hadassit Bio Holdings in 2025: The Portfolio Is Almost Gone, Leaving a Shell, a Small Cash Balance, and a Lawsuit

Company Introduction

It is easy to misread Hadassit Bio as a weakened life-sciences holding company that simply had another bad year. That is no longer the right frame. By the end of 2025 the company held two residual positions, Kahr and SelCure, both carried near zero, with no quoted asset left on the balance sheet, no real operating activity generating revenue, and an explicit exchange and regulatory classification as a shell company.

What is actually working now? The company still has a live listed platform, controlling shareholders who are still willing to provide bridge funding, and a legal process around SelCure and Lineage that could, at least in theory, unlock value. That is not nothing. But it is also not an operating business. The active bottleneck is different: cash is not enough for 12 months from the financial-statement approval date, while the shell clock is already running.

That matters now because the market still prices the company above pure cash. On April 3, 2026 the share traded at 75.5 agorot, implying a market cap of roughly NIS 8.4 million based on the issued share count. Against that, the company ended 2025 with only NIS 1.485 million of cash and cash equivalents, and by the time the board approved the statements the balance had already fallen to NIS 1.199 million. In other words, the market is not reading the company as cash alone. It is assigning some value to the lawsuit option, the shell option, or both.

The surface reading also becomes misleading through the bottom line. Loss fell to NIS 1.708 million from NIS 3.519 million in 2024. That is not necessarily an improvement. In this case, the smaller loss mostly means there was almost nothing left to mark down. Enlivex, the last quoted asset, was sold. Kahr had already been pushed to zero in prior years. SelCure remains near zero because the company still does not hold enough information to assign it a higher value.

The quick economic map looks like this:

This chart is the core of the story. The company put NIS 46.027 million into Kahr over time and another NIS 3.452 million into SelCure. By the end of 2025 both are carried at roughly zero. That is why this is no longer a "life-sciences portfolio waiting for maturity" story. It is a story about what can still be salvaged from the shell that remains.

There is also an important pre-cycle setup point. In December 2024 Hadassit and Centaurus published a full tender offer for all public shares at NIS 0.526 per share, for total consideration of NIS 1.458 million. In January 2025 the attempt failed because only 789,080 shares, about 7.04% of the company, were tendered. That matters because it shows the controlling shareholders first tried to take the company private at a relatively low price, failed, and then shifted to a different model, keeping the shell alive through targeted funding.

Events And Triggers

The failed tender-offer exit

The first key 2025 event happened at the very start of the year. The failure of the full tender offer left the company public instead of allowing the controllers to close the story outside the exchange. This was not just a technical event. It is what kept the shell option alive.

The move from asset sales to bridge financing

During 2025 the company, through Tolaren, sold its remaining 398,307 Enlivex shares for NIS 1.739 million. After paying NIS 400 thousand of tax, investing cash flow contributed NIS 1.339 million. That sale also closed the last quoted asset. From that point on, the company was no longer funding itself from portfolio realizations. It was increasingly funding itself from shareholder support.

The December 2025 related-party loan

On December 1, 2025 the company received a USD 350 thousand loan from one of its major shareholders. Under the agreement, the loan bears no interest, has no collateral, and matures 14 months after drawdown or within 7 business days after the company receives proceeds equal to or above the loan amount from the SelCure legal process, whichever comes first. This is a material trigger because it improves liquidity immediately, while also showing that the bridge is directly tied to the same legal option the company is trying to monetize.

Management and board changes

On May 14, 2025 Miriam Valensi Tovli was appointed CFO and acting CEO in place of the late Yoram Azulai, who passed away early in the year. At the end of December 2025 Asher Elhayany left the board, while Yuval Eder's term was renewed and Dr. David Zchut was appointed as a director. These are meaningful continuity events at the governance level, but they do not change the economics. Even after the refresh, the core issue remains cash, shell status, and litigation.

March 2026, the document-discovery process was deleted, not the dispute

The SelCure and Lineage dispute did not end, but it did change form. A court-appointed expert opinion was submitted in June 2025 and remains sealed. After two mediation meetings in November and December 2025 that, according to the company, produced no meaningful progress, the company asked in January 2026 to end the document-discovery process so it could move to a more suitable legal route. On March 12, 2026 the court deleted that proceeding, and the company says it is now reviewing its next steps and the possibility of publishing the expert opinion or its conclusions. This is a real market trigger because if the market gets clarity on what the expert concluded, it will have its first external anchor for an option that is still almost entirely off the balance sheet.

Efficiency, Profitability And Competition

For a company like this, the efficiency question is not whether margins improved. There is no operating sales engine to analyze. The real question is how much it costs to keep the shell alive, and how much of the P&L still reflects business economics rather than the maintenance cost of a public company.

The numbers themselves are sharp. In 2025 the company recorded only NIS 63 thousand of income, NIS 39 thousand from fair-value movement and NIS 24 thousand from finance income. Against that, it carried NIS 1.667 million of general and administrative expense and NIS 100 thousand of finance expense. So almost the entire income statement is really a compact version of one question, how expensive is it to keep the public shell functioning?

This chart shows why the smaller 2025 loss is misleading. In 2023 and 2024 the loss still reflected large value write-downs. By 2025 the fair-value line had already flipped to a tiny NIS 39 thousand gain. That is not a quality jump. It is the result of there being almost nothing left to measure.

The more interesting layer is the cost structure. The company had only one employee at the report date, it operated without permanent offices, and in 2025 it decided not to conduct internal audit work because it had no real operating activity. Even so, general and administrative expense still stood at NIS 1.667 million.

The point is not only that the cost base is high relative to the size of the company. The more important point is that the weight has shifted toward professional services, NIS 1.049 million in 2025. That means what is keeping the company alive is not a team, a product or a revenue engine. It is a legal, accounting and governance wrapper that allows it to remain an active public platform.

That is also where the company's real "competition" now sits, if the word even fits. Hadassit Bio is no longer competing directly for product-market fit through its own activity. It is competing for three other things, time, funding, and the ability to bring in an appropriate new activity before the shell erodes further. That is harder to measure, but more real than any classic discussion of margins or market share.

There is another yellow flag that matters. The company says it has never received dividends from its portfolio companies, and due to its limited financial resources it no longer participates in financing rounds of its current portfolio holdings and is no longer looking for new portfolio investments. In other words, the shift from holding company to shell is now visible at the management level as well, not only in the accounting.

This chart shows the final move from portfolio to liquidity. In 2024 there was still a quoted financial asset on the balance sheet, Enlivex. In 2025 it was gone. What remains at the current-asset level is cash and almost nothing else.

Cash Flow, Debt And Capital Structure

The right frame here is all-in cash flexibility. This is not a company that can currently be judged through normalized recurring cash generation because there is no operating business to normalize. The relevant question is how much real cash remains after the actual uses.

In 2025 operating cash outflow was NIS 1.729 million. Investing cash flow contributed NIS 1.339 million thanks to the Enlivex sale, net of tax. Financing cash flow contributed another NIS 1.097 million because of the major-shareholder loan. In the end, cash rose to NIS 1.485 million, but that increase was built from an asset realization and outside support, not from operations.

The right reading of this chart is that the company is not generating time. It is buying time. In earlier years it bought time by selling Enlivex shares. In 2025 it had to add a shareholder loan as well.

The balance-sheet picture is even sharper. Equity fell from a NIS 1.662 million surplus at the end of 2024 to a NIS 17 thousand deficit at the end of 2025. Working capital also moved from a NIS 2.037 million surplus to a NIS 17 thousand deficit. In other words, the company crossed the line from being a shell with a small cushion into being a shell already operating around zero.

That matters because the erosion in equity is not only an accounting aesthetic. To exit shell status and return to the main list, the company will have to satisfy the listing conditions of a new company, including equity, public-holdings value and minimum spread. So even if a merger target is found, that alone will not solve the problem. A capital layer will still be needed.

The structure of the loan tells its own story. In nominal terms the company received NIS 1.142 million. On initial recognition it was measured at fair value of NIS 1.050 million, based on discounting at a 7.5% market rate, and the difference was credited to equity. That may sound technical, but the message is simple, the major shareholder did not provide an ordinary commercial loan. It provided a bridge that also contained an equity-support component.

Still, that should not be overstated. The company has no bank credit at all, and the auditor explicitly highlights significant doubt about the company's ability to continue as a going concern. The company also has FX exposure, though it is secondary to the broader picture. At the end of 2025 it held USD-linked assets of NIS 1.413 million against USD-linked liabilities of NIS 1.032 million, and a 5% move in the shekel against the dollar would affect loss by NIS 19 thousand. That is not what breaks the thesis, but it does show that even the thin cash box is not fully insulated.

Outlook

Before looking forward, four non-obvious findings need to be fixed in place:

• The lower 2025 loss is not evidence of improving business quality. It mostly reflects the fact that there is almost nothing left to mark down.
• Cash at the statement approval date, NIS 1.199 million, is a shorter runway than the year-end balance alone suggests.
• A future merger would not automatically solve the problem because shell exit also requires renewed compliance with fresh-listing conditions.
• Even the bridge funding already received is linked to the SelCure option, so it does not create a separate thesis. It only slightly extends the clock.

What has to happen for the shell to remain relevant

The company says it is examining the introduction of a new activity in the coming months. That matters, but it is still very general. For the market to improve its read, it will need to see an activity with real economics, something that can generate or at least be expected to generate ordinary-course revenue, not another passive financial asset or residual stake. Otherwise the company may remain a shell even after a transaction.

That is where the preservation-list clock comes in. The company's trading already moved to the preservation list in 2023, and the company explains that if the conditions for returning to the main list are not met within 48 months from the date the shares ceased trading there, by May 6, 2028, the securities will be delisted. Formally that still looks distant. Economically it is much closer because the current funding bridge ends far earlier.

Why SelCure is an option, not a forecast base

The big temptation is to read SelCure as a hidden asset. There is a factual basis for that reading. According to information available to the company, the SelCure collaboration with Roche and Genentech included a USD 50 million upfront payment, up to USD 620 million in milestone payments, and double-digit royalties on net sales of OpRegen. The problem starts in the next layer. The company argues that in parallel SelCure signed an agreement with Lineage under which part of those rights was transferred to the controlling shareholder for only about USD 31.7 million.

That sounds material, but it would be a mistake to over-fuse the facts. The company itself emphasizes that it still does not have full information on the agreements and cash allocation, so it continues to carry the holding near zero. The court expert opinion submitted in June 2025 is also still sealed. So as of 2025 and March 2026, SelCure remains a legal option rather than a measurable value anchor.

Even the tax shield is not accessible value yet

The company has tax-loss carryforwards of about NIS 71.8 million and capital-loss carryforwards of about NIS 2.4 million. On paper that can look like an asset. In practice the company does not recognize deferred tax assets for those losses, beyond a very small amount already offset, because it does not expect future taxable profits that would allow their use in the foreseeable future. This is a classic gap between theoretical value and accessible value. Even the tax shield exists only if a profitable activity is eventually brought in.

How 2026 should really be read

The right name for the coming year is a bridge-and-decision year. A bridge year because the company is still burning cash mainly to preserve corporate continuity and optionality. A decision year because at some point it will have to choose, raise capital, bring in real activity, or return again to the major shareholders for more support. The filing says this explicitly, the company may approach its major shareholders for additional financing.

From a market perspective, that means the near-term triggers are not accounting-based. The market is likely to watch three things, whether there is real progress on a new activity, whether fresh financing arrives, and whether SelCure gets a clearer legal anchor. If one of those happens, the stock can look very different quite quickly. If all three stall, May 2028 will start to look much less remote.

Risks

Liquidity is the central risk

This is the clearest risk, but also the easiest one to understate because debt is small. The company has no bank debt, no meaningful quoted assets left to monetize, and an explicit going-concern warning. So the risk is not classical leverage. It is simply lack of time.

Shell status is not only a regulatory risk, but a commercial one

The preservation list reduces trading hours and liquidity, and makes the stock a weaker acquisition currency. At the same time, shell status itself weakens the company's bargaining power against any potential activity that may want to enter the market through it.

SelCure risk is really a value-access risk

There may well be a real economic grievance here. There may also not be. But until the company gets fuller information, moves to the right legal process, and gives the market a clearer monetization path, SelCure remains more story than asset. That matters even more because the major-shareholder loan is also linked, in its repayment terms, to possible proceeds from the same direction.

The Tolaren legal noise has not fully disappeared

In June 2025 Professor Dror Mevorach argued that he was entitled to 50% of the Enlivex shares held by Tolaren after Tolaren decided to sell them and distribute the proceeds. The company rejected the claims outright, and as of the report-signing date no formal claim had been filed. This is not the main risk, but it is a reminder that even a very thin shell can still carry legal tails.

No short data does not eliminate actionability risk

No short-interest data is available for this company. That is neither a positive nor a negative signal by itself. The practical meaning is that the stock's reading will remain almost entirely tied to corporate events rather than to a technical market signal from short positioning.

Conclusions

Hadassit Bio ends 2025 not as a weakened biotech company, but as a public shell trying to buy time. What supports it right now is the fact that it still exists as a listed platform, the bridge loan already received, and the possibility that SelCure eventually yields value. What blocks a cleaner thesis is that this time window is short, and the shell itself is already operating around the zero line. In the short to medium term, market reaction is likely to depend mainly on fresh financing, new activity, or a legal development that can finally be quantified.

Current thesis: Hadassit Bio is no longer a portfolio thesis. It is now a shell, bridge-funding, and legal-option thesis.

What really changed? The company moved from a world in which it still had a quoted asset and remnants of a biotech portfolio into a world where the last quoted asset is gone, the Kahr stake is economically marginal, SelCure remains near zero, and the debate has shifted from portfolio value to time.

The strongest counter-thesis is that the market may actually be reading the company correctly, not as a tiny cash box, but as a cheap option on three things at once, the lawsuit, the tax shield, and the listed shell platform. If one of those matures, today's balance sheet may prove too conservative.

What could change the market's reading? Additional financing from controlling shareholders or a third party, publication or clearer use of the SelCure expert opinion, or the identification of a new activity with real economics.

Why does this matter? Because this is a classic case where accounting value has almost disappeared, but the question of whether there is still accessible value for shareholders remains open.

Over the next 2 to 4 quarters, the thesis strengthens if the company brings in a new activity with real economics, secures funding beyond the current bridge loan, or turns SelCure from a vague dispute into a more defined monetization path. It weakens if cash keeps burning without such an event and the shell continues merely buying time instead of building a solution.